Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy

• 발행기관: 대한안과학회
• 저자명: Jaeryung Oh Chang Ki Yoon Bo Hee Kim Hyeong Gon Yu
• 간행물 정보: 『The Korean Journal of Ophthalmology』Vol.35 No.1, 51~63쪽, 전체 13쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2021.02.28

영문 초록

Purpose: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttriumlithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). Methods: This randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, allsubjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primaryoutcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondaryoutcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-monthexaminations. Results: Sixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF wasachieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant(p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction ofSRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, -59.7 μm; 95% confidenceinterval, -98.2 to -21.2; p = 0.0029; least squares mean difference -67.0 μm; 95% confidence interval, -104.8 to -29.2;p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRTgroup (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant inSRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed. Conclusions: SRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in thistrial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patientswith acute symptomatic CSC.

목차

Materials and Methods

Results

Discussion

Conflict of Interest

Acknowledgements

Supplemental Material

References

키워드

Central serous chorioretinopathy Clinical trial Laser treatment Subthreshold micropulse laser